Axxcess Wealth Management LLC Makes New $227,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Axxcess Wealth Management LLC bought a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 22,997 shares of the company’s stock, valued at approximately $227,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. First Horizon Advisors Inc. acquired a new position in Recursion Pharmaceuticals during the fourth quarter valued at approximately $47,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Recursion Pharmaceuticals by 116.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,237 shares of the company’s stock worth $40,000 after buying an additional 2,817 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Recursion Pharmaceuticals by 25.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company’s stock worth $77,000 after buying an additional 2,050 shares during the last quarter. Private Advisor Group LLC acquired a new stake in Recursion Pharmaceuticals in the third quarter valued at about $79,000. Finally, Plancorp LLC bought a new position in Recursion Pharmaceuticals in the third quarter valued at about $82,000. Institutional investors own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on RXRX shares. Needham & Company LLC restated a “buy” rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. KeyCorp boosted their target price on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Finally, TD Cowen assumed coverage on Recursion Pharmaceuticals in a report on Friday, January 26th. They set a “market perform” rating on the stock. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $12.75.

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX opened at $8.64 on Friday. Recursion Pharmaceuticals, Inc. has a one year low of $4.92 and a one year high of $16.75. The company has a market cap of $2.03 billion, a PE ratio of -5.57 and a beta of 0.85. The firm’s 50 day simple moving average is $9.45 and its 200 day simple moving average is $9.25.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The firm had revenue of $10.89 million during the quarter, compared to the consensus estimate of $12.37 million. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current year.

Insider Buying and Selling

In related news, COO Tina Marriott sold 8,000 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $14.89, for a total value of $119,120.00. Following the sale, the chief operating officer now owns 639,982 shares of the company’s stock, valued at $9,529,331.98. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Recursion Pharmaceuticals news, COO Tina Marriott sold 8,000 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $14.89, for a total transaction of $119,120.00. Following the sale, the chief operating officer now owns 639,982 shares of the company’s stock, valued at $9,529,331.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $8.82, for a total transaction of $100,962.54. Following the sale, the director now directly owns 7,241,308 shares in the company, valued at approximately $63,868,336.56. The disclosure for this sale can be found here. Insiders have sold a total of 352,946 shares of company stock valued at $3,485,453 over the last 90 days. 15.75% of the stock is owned by insiders.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.